TY - JOUR
T1 - Beta 2-microglobulin elimination characteristics during hemofiltration with acrylonitrile and polysulfone membrane hemofilters
AU - Kandus, A.
AU - Ponikvar, R.
AU - Drinovec, J.
AU - Pavlin, K.
AU - Ivanovich, P.
PY - 1990
Y1 - 1990
N2 - Elimination characteristics of beta 2 -microglobulin (BMG) during hemofiltration (HF) with acrylonitrile (AN69) and polysulfone (PS) hemofilters were investigated in a prospective clinical investigation. Seven chronic uremics on regular HF were treated for 4 weeks, three times a week, with AN69 hemofilters. The study was then repeated with PS hemofilters. There were no significant differences in the patients' body weight, the ultrafiltrate volume per session, and the duration of each HF session between both treatments. At the start of HF, arterial plasma concentration of BMG was (for AN69) 33.5±4.0 mg/L (mean±SD) and (for PS) 35.8±6.5 mg/L (NS); at the end of HF it was (for AN69) 11.0±1.8 mg/L and (for PS) 17.5 ±4.2 mg/L (p<0.001). The amount of BMG in total ultrafiltrate was (for AN69) 179.3±22.6 mg and (for PS) 140.6±26.8 mg (p<0.02). With AN69 hemofilter,maximum BMG plasma clearance and sieving coefficient were 51.0±9.5 mL/min' and 0.42±0.04 at 60 minutes. With PS hemofilter, maximum BMG plasma clearance and sieving coefficient were 37.4±5.7 mL/min and 0.27±0.03 at 15 minutes. Twenty-two percents of BMG entering the AN69 hemofilter at 15 minutes were adsorbed on the membrane (p<0.001). BMG elimination with the AN69 hemofilter was more efficient than with the PS hemofilter. Long-term studies will be necessary to demonstrate whether this difference is of any clinical significance.
AB - Elimination characteristics of beta 2 -microglobulin (BMG) during hemofiltration (HF) with acrylonitrile (AN69) and polysulfone (PS) hemofilters were investigated in a prospective clinical investigation. Seven chronic uremics on regular HF were treated for 4 weeks, three times a week, with AN69 hemofilters. The study was then repeated with PS hemofilters. There were no significant differences in the patients' body weight, the ultrafiltrate volume per session, and the duration of each HF session between both treatments. At the start of HF, arterial plasma concentration of BMG was (for AN69) 33.5±4.0 mg/L (mean±SD) and (for PS) 35.8±6.5 mg/L (NS); at the end of HF it was (for AN69) 11.0±1.8 mg/L and (for PS) 17.5 ±4.2 mg/L (p<0.001). The amount of BMG in total ultrafiltrate was (for AN69) 179.3±22.6 mg and (for PS) 140.6±26.8 mg (p<0.02). With AN69 hemofilter,maximum BMG plasma clearance and sieving coefficient were 51.0±9.5 mL/min' and 0.42±0.04 at 60 minutes. With PS hemofilter, maximum BMG plasma clearance and sieving coefficient were 37.4±5.7 mL/min and 0.27±0.03 at 15 minutes. Twenty-two percents of BMG entering the AN69 hemofilter at 15 minutes were adsorbed on the membrane (p<0.001). BMG elimination with the AN69 hemofilter was more efficient than with the PS hemofilter. Long-term studies will be necessary to demonstrate whether this difference is of any clinical significance.
UR - http://www.scopus.com/inward/record.url?scp=0025313478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025313478&partnerID=8YFLogxK
U2 - 10.1177/039139889001300402
DO - 10.1177/039139889001300402
M3 - Article
C2 - 2197235
AN - SCOPUS:0025313478
SN - 0391-3988
VL - 13
SP - 200
EP - 204
JO - International Journal of Artificial Organs
JF - International Journal of Artificial Organs
IS - 4
ER -